128 related articles for article (PubMed ID: 19762240)
1. The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction.
Knust H; Achermann G; Ballard T; Buettelmann B; Gasser R; Fischer H; Hernandez MC; Knoflach F; Koblet A; Stadler H; Thomas AW; Trube G; Waldmeier P
Bioorg Med Chem Lett; 2009 Oct; 19(20):5940-4. PubMed ID: 19762240
[TBL] [Abstract][Full Text] [Related]
2. Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA alpha5 inverse agonists with potential for the treatment of cognitive dysfunction.
Buettelmann B; Ballard TM; Gasser R; Fischer H; Hernandez MC; Knoflach F; Knust H; Stadler H; Thomas AW; Trube G
Bioorg Med Chem Lett; 2009 Oct; 19(20):5958-61. PubMed ID: 19740657
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABA(A) alpha5 inverse agonist series.
Achermann G; Ballard TM; Blasco F; Broutin PE; Büttelmann B; Fischer H; Graf M; Hernandez MC; Hilty P; Knoflach F; Koblet A; Knust H; Kurt A; Martin JR; Masciadri R; Porter RH; Stadler H; Thomas AW; Trube G; Wichmann J
Bioorg Med Chem Lett; 2009 Oct; 19(19):5746-52. PubMed ID: 19726184
[TBL] [Abstract][Full Text] [Related]
4. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.
Atack JR
Curr Top Med Chem; 2011; 11(9):1203-14. PubMed ID: 21050171
[TBL] [Abstract][Full Text] [Related]
5. Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality.
Jacobsen EJ; Stelzer LS; TenBrink RE; Belonga KL; Carter DB; Im HK; Im WB; Sethy VH; Tang AH; VonVoigtlander PF; Petke JD; Zhong WZ; Mickelson JW
J Med Chem; 1999 Apr; 42(7):1123-44. PubMed ID: 10197957
[TBL] [Abstract][Full Text] [Related]
6. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.
Ballard TM; Knoflach F; Prinssen E; Borroni E; Vivian JA; Basile J; Gasser R; Moreau JL; Wettstein JG; Buettelmann B; Knust H; Thomas AW; Trube G; Hernandez MC
Psychopharmacology (Berl); 2009 Jan; 202(1-3):207-23. PubMed ID: 18936916
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site.
Street LJ; Sternfeld F; Jelley RA; Reeve AJ; Carling RW; Moore KW; McKernan RM; Sohal B; Cook S; Pike A; Dawson GR; Bromidge FA; Wafford KA; Seabrook GR; Thompson SA; Marshall G; Pillai GV; Castro JL; Atack JR; MacLeod AM
J Med Chem; 2004 Jul; 47(14):3642-57. PubMed ID: 15214791
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives.
Gitto R; Orlando V; Quartarone S; De Sarro G; De Sarro A; Russo E; Ferreri G; Chimirri A
J Med Chem; 2003 Aug; 46(17):3758-61. PubMed ID: 12904081
[TBL] [Abstract][Full Text] [Related]
9. The proconvulsant effects of the GABAA alpha5 subtype-selective compound RY-080 may not be alpha5-mediated.
Atack JR; Bayley PJ; Fletcher SR; McKernan RM; Wafford KA; Dawson GR
Eur J Pharmacol; 2006 Oct; 548(1-3):77-82. PubMed ID: 16962577
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognition.
Chambers MS; Atack JR; Broughton HB; Collinson N; Cook S; Dawson GR; Hobbs SC; Marshall G; Maubach KA; Pillai GV; Reeve AJ; MacLeod AM
J Med Chem; 2003 May; 46(11):2227-40. PubMed ID: 12747794
[TBL] [Abstract][Full Text] [Related]
11. 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1.
Carling RW; Moore KW; Street LJ; Wild D; Isted C; Leeson PD; Thomas S; O'Connor D; McKernan RM; Quirk K; Cook SM; Atack JR; Wafford KA; Thompson SA; Dawson GR; Ferris P; Castro JL
J Med Chem; 2004 Mar; 47(7):1807-22. PubMed ID: 15027873
[TBL] [Abstract][Full Text] [Related]
12. γ-Aminobutyric acid type A (GABA(A)) receptor subtype inverse agonists as therapeutic agents in cognition.
Gabriella G; Giovanna C
Methods Enzymol; 2010; 485():197-211. PubMed ID: 21050918
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.
Atack JR
Pharmacol Ther; 2010 Jan; 125(1):11-26. PubMed ID: 19770002
[TBL] [Abstract][Full Text] [Related]
14. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.
Atack JR; Bayley PJ; Seabrook GR; Wafford KA; McKernan RM; Dawson GR
Neuropharmacology; 2006 Nov; 51(6):1023-9. PubMed ID: 17046030
[TBL] [Abstract][Full Text] [Related]
15. Imidazo[1,2-b][1,2,4]triazines as alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.
Jennings AS; Lewis RT; Russell MG; Hallett DJ; Street LJ; Castro JL; Atack JR; Cook SM; Lincoln R; Stanley J; Smith AJ; Reynolds DS; Sohal B; Pike A; Marshall GR; Wafford KA; Sheppard WF; Tye SJ
Bioorg Med Chem Lett; 2006 Mar; 16(6):1477-80. PubMed ID: 16386900
[TBL] [Abstract][Full Text] [Related]
16. RO4938581, a GABAAα5 modulator, displays strong CYP1A2 autoinduction properties in rats.
Bundgaard C; Badolo L; Redrobe JP
Biochem Pharmacol; 2013 May; 85(9):1363-9. PubMed ID: 23415905
[TBL] [Abstract][Full Text] [Related]
17. 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models.
Carling RW; Madin A; Guiblin A; Russell MG; Moore KW; Mitchinson A; Sohal B; Pike A; Cook SM; Ragan IC; McKernan RM; Quirk K; Ferris P; Marshall G; Thompson SA; Wafford KA; Dawson GR; Atack JR; Harrison T; Castro JL; Street LJ
J Med Chem; 2005 Nov; 48(23):7089-92. PubMed ID: 16279764
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and pharmacological evaluation of novel 1,2,4-triazol-3-amine derivatives as potential agonists of GABA
Jahani R; Reza Abtahi S; Nematpour M; Fasihi Dastjerdi H; Chamanara M; Hami Z; Paknejad B
Bioorg Chem; 2020 Nov; 104():104212. PubMed ID: 32916390
[TBL] [Abstract][Full Text] [Related]
19. Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.
Redrobe JP; Elster L; Frederiksen K; Bundgaard C; de Jong IE; Smith GP; Bruun AT; Larsen PH; Didriksen M
Psychopharmacology (Berl); 2012 Jun; 221(3):451-68. PubMed ID: 22124672
[TBL] [Abstract][Full Text] [Related]
20. Discovery of ONO-8590580: A novel, potent and selective GABA
Lewis A; Beresford A; Chambers MS; Clark G; Hartley DC; Hirst KL; Higashino M; Kawahadara S; Nakanishi M; Saito T; Imagawa A; Habashita H; Maidment S; Macleod AM; Owens AP; Rae A; Rouse C; Wishart G
Bioorg Med Chem Lett; 2020 Nov; 30(22):127536. PubMed ID: 32898695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
